1 The heart of a hibernator: EGFR and MAPK signaling in cardiac muscle during the hibernation of thirteen-lined ground squirrels, .

2 Exploration of Pd-catalysed four-component tandem reaction for one-pot assembly of pyrazolo[1,5-c]quinazolines as potential EGFR inhibitors.

3 Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells.

4 pH-Responsive polyelectrolyte coated gadolinium oxide-doped mesoporous silica nanoparticles (GdO@MSNs) for synergistic drug delivery and magnetic resonance imaging enhancement.

5 Clinicopathological and immunohistochemical characteristics of breast cancer patients from Northeast India with special reference to triple negative breast cancer: A prospective study.

6 EHD1 and RUSC2 Control Basal Epidermal Growth Factor Receptor Cell Surface Expression and Recycling.

7 Immediate Dental Implant Stabilization in a Canine Model Using a Novel Mineral-Organic Adhesive: 4-Month Results.

8 synthesis, molecular docking and biological evaluation of glycyrrhizin analogs as anticancer agents targeting egfr

9 a pilot study (swog s0429) of weekly cetuximab and chest radiotherapy for poor-risk stage iii non-small cell lung cancer

10 survival predictors in paraquat intoxification and role of immunosuppression

11 thyroid dysfunctions and renal status: implications in hyponatremia

12 association between cd47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer

13 role of the expression level of nrf2 in predicting response of egfr-tkis  in lung adenocarcinoma patients with egfr gene mutations

14 identification and characterization of egf receptor in individual exosomes by fluorescence-activated vesicle sorting

15 reversing egfr mediated immunoescape by targeted monoclonal antibody therapy

16 the association of daily activity levels and estimated kidney function in men and women with predialysis chronic kidney disease

17 universal insertion/deletion-enrich pcr

18 non-small cell carcinoma biomarker testing: the pathologist's perspective.

19 induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice

20 new developments in the treatment of advanced squamous cell lung cancer: focus on afatinib

21 folliculin interacts with rab35 to regulate egf-induced egfr degradation

22 response to her2 inhibition in a patient with brain metastasis with egfr tki acquired resistance and an her2 amplification

23 estimated glomerular filtration rate (egfr): a serum creatinine-based test for the detection of chronic kidney disease and its impact on clinical practice

24 an immunohistochemical study of egfr expression in colorectal cancer and its correlation with lymph nodes status and tumor grade

25 mechanisms of activation of receptor tyrosine kinases: monomers or dimers

26 Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.

27 Omicron N501Y mutation among SARS-CoV-2 lineages: In-silico analysis of potent binding to tyrosine kinase and hypothetical repurposed medicine.

28 Omicron variant and booster COVID-19 vaccines.

29 Another year another variant: COVID 3.0-Omicron.

30 SARS-CoV-2 Omicron Variant: Could it be Another Threat?

31 Exploring the potential of biologically active phenolic acids from marine natural products as anticancer agents targeting the epidermal growth factor receptor.

32 Synthesis and biological evaluation of 2.4 nm thiolate-protected gold nanoparticles conjugated to Cetuximab for targeting glioblastoma cancer cells via the EGFR.

33 Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors.

34 Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents.

35 Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing.

36 Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.

37 EGFR signaling in colorectal cancer: a clinical perspective

38 EGFR signaling in colorectal cancer: a clinical perspective

39 EGFR signaling in colorectal cancer: a clinical perspective

40 New amide linked dimeric 1,2,3-triazoles bearing aryloxy scaffolds as a potent antiproliferative agents and EGFR tyrosine kinase phosphorylation inhibitors.

41 Synthesis and preclinical investigation of Tc-p-SCN-Bzl-DTPA-cetuximab for targeting EGFR using head and neck squamous cell carcinoma (HNSCC) xenografts.

42 Pyrazolo-benzothiazole hybrids: Synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model.

43 KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program

44 Interleukin 1 beta and Matrix Metallopeptidase 3 Contribute to Development of EGFR-dependent Serrated Polyps in Mouse Cecum.

45 Icariin and icaritin stimulate the proliferation of SKBr3 cells through the GPER1-mediated modulation of the EGFR-MAPK signaling pathway.

46 EGFR inhibition studies by hybrid scaffolds for their activity against ovarian cancer.

47 Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.

48 Correction: Kaempferol inhibits angiogenesis by suppressing hif-1α and vegfr2 activation via erk/p38 mapk and pi3k/akt/mtor signaling pathways in endothelial cells (Preventive Nutrition and Food Science (2017) 22: 4 (320-326)

49 Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer.

50 Single-cell RNA-seq reveals RAD51AP1 as a potent mediator of EGFRvIII in human glioblastomas.

51 Decreased eGFR Is Associated With Ischemic Stroke in Patients With Dilated Cardiomyopathy.

52 Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.

53 Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors

54 Synthesis of Triazole-Substituted Quinazoline Hybrids for Anticancer Activity and a Lead Compound as the EGFR Blocker and ROS Inducer Agent

55 Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities.

56 Synthesis, molecular docking, and evaluation of novel bivalent pyrazolinyl-1,2,3-triazoles as potential VEGFR TK inhibitors and anti-cancer agents

57 ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.

58 EGFR signaling promotes β-cell proliferation and survivin expression during pregnancy.

59 Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.

60 Ibrutinib potentiates anti-hepatocarcinogenic efficacy of sorafenib by targeting EGFR in tumor cells and BTK in immune cells in the stroma.

61 Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR > 60 mL/min/1.73 m and negative proteinuria.

62 Highly sensitive and specific real-time PCR by employing serial invasive reaction as a sequence identifier for quantifying EGFR mutation abundance in cfDNA.

63 Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.

64 Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.

65 Asporin enhances colorectal cancer metastasis through activating the EGFR/src/cortactin signaling pathway

66 Vascular Endothelial Growth Factor A and VEGFR-1 Change during Preimplantation in Heifers.

67 Corrigendum to ‘Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2’ [European journal of medicinal chemistry 158 (2018) 814–831](S0223523418308225)(10.1016/j.ejmech.2018.09.050)

68 Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles.

69 Prospective pediatric study comparing glomerular filtration rate estimates based on motion-robust dynamic contrast-enhanced magnetic resonance imaging and serum creatinine (eGFR) to Tc DTPA.

70 Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.

71 Correction to: EGFR signaling augments TLR4 cell surface expression and function in macrophages via regulation of Rab5a activation.

72 Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDH wt astrocytoma to glioblastoma

73 a high expression egfr/cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening egfr antagonists from rhizoma polygoni cuspidati

74 quantitative analysis of [11c]-erlotinib pet demonstrates specific binding for activating mutations of the egfr kinase domain

75 severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring egfr mutation

76 serum zag levels were associated with egfr mild decrease in t2dm patients with diabetic nephropathy

77 tyrosine kinase inhibitors in egfr-mutated large-cell neuroendocrine carcinoma of the lung a case report

78 egfr protein expression using a specific intracellular domain antibody and pten and clinical outcomes in squamous cell lung cancer patients with egfr-tyrosine kinase inhibitor therapy

79 tgf-β and hypoxia/reoxygenation promote radioresistance of a549 lung cancer cells through activation of nrf2 and egfr

80 vascular endothelial growth factor and its soluble receptors vegfr-1 and vegfr-2 in the serum of patients with systemic lupus erythematosus

81 formyl peptide receptor 1 modulates endothelial cell functions by nadph oxidase-dependent vegfr2 transactivation

82 mir-sc8 inhibits schwann cell proliferation and migration by targeting egfr.

83 spectrum of egfr gene copy number changes and kras gene mutation status in korean triple negative breast cancer patients.

84 chemotherapy and egfr tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients

85 quantum dots immunofluorescence histochemical detection of egfr gene mutations in the non-small cell lung cancers using mutation-specific antibodies

86 expressions of c-cbl, cbl-b and egfr and its role of prognosis in nsclc

87 siegfried j. schmidt: kalte faszination. medien-kultur-wissenschaft

88 the immune system's contribution to the clinical efficacy of egfr antagonist treatment

89 the involvement of kras gene 3'-utr polymorphisms in risk of cancer and influence on patient response to anti-egfr therapy in metastatic colorectal cancer: a meta-analysis

90 clinical analysis of icotinib on beneficiary of  advanced non-small cell lung cancer with egfr common mutation

91 expression of egfrviii in glioblastoma: prognostic significance revisited

92 egfr-targeted delivery of dox-loaded fe3o4@polydopamine multifunctional nanocomposites for mri and antitumor chemo-photothermal therapy

93 first-line treatment in egfr mutant non-small cell lung cancer: is there a best option?

94 the detection methods of egfr mutations in non-small cell lung cancer

95 endosome-to-plasma membrane recycling of vegfr2 receptor tyrosine kinase regulates endothelial function and blood vessel formation

96 antibacterial and egfr-tyrosine kinase inhibitory activities of polyhydroxylated xanthones from garcinia succifolia

97 kir genes and their ligands predict the response to anti-2 egfr monoclonal antibodies in solid tumors

98 gene expression of the egf system—a prognostic model in non–small cell lung cancer patients without activating egfr mutations

99 comparison of the superarms and droplet digital pcr for detecting egfr mutation in ctdna from nsclc patients

100 siegfried kracauer: penseur de l´histoire

101 outcomes of research biopsies in clinical trials of egfr mutation-positive non-small cell lung cancer patients pretreated with egfr-tyrosine kinase inhibitors

Keyword Connections

Journals

Research Groups

Bibliographies